The Operating System of Modern Private Equity — Playbook — reengineered against Investment Committee scrutiny: independent verification, counterfactual discipline, succession risk, legal review, portfolio resourcing, defined escalation authority, and calibratable operating parameters.

This Playbook has two intended readers, and they should not read it the same way.

PE sponsors and Operating Partners are the governance owners. Read Sections 1–5, 7, 8, 13, and the new Sponsor Vetting Checklist below before approving rollout to any portfolio company. These sections define what the sponsor is committing to enforce — the escalation authority, the legal-review gate, and the portfolio-level time cost — and are the sections an Investment Committee should review before this Playbook is adopted fund-wide.

Portfolio-company leadership — the CEO, CFO, CHRO, or President who will actually run it — should read Section 6 (the Implementation Roadmap) and Section 14 (Monday Morning Actions) as their working document. Everything they need to execute is there; the governance rationale behind it lives in the sections above.

Before this Playbook is rolled out to a portfolio company, a sponsor should be able to check each of the following:

A cost line can be fully staffed, competently run, and completely ungoverned at the same time. HR spend is the proof case: it doubled twice as a share of operating expense between 2017 and 2025 while the outcome the function most directly owns — employee engagement — fell to a five-year low, and no one inside a typical portfolio company was ever structurally required to explain the relationship either way. The economics are not abstract. McKinsey's own G&A research prices the adjacent opportunity at 3 points of EBITDA and 25%-plus of enterprise value at exit. This Playbook exists to close the gap between what a portfolio company could measure and what anyone is actually required to measure. The management behavior that must change is narrow and specific: before any G&A budget increase is approved, one named owner states in advance what the increase is expected to produce, that hypothesis is checked against what would have happened anyway, and the result is verified by someone other than the owner before it counts. This revision exists because the first version left that verification step out — a gap that would not have survived a real Investment Committee review.

No function inside a typical portfolio company — CFO, CHRO, deal team, or Operating Partner — holds all four conditions required for accountability: information, authority, incentive, and accountability itself. Each function typically holds one or two of the four. None holds all four. A cost line with distributed partial ownership behaves exactly like a cost line with no ownership at all, and it will keep growing on assumption rather than evidence for as long as that remains true. This principle is repeatable because the four-condition test is function-agnostic — it applies to HR today and, without modification, to procurement, working capital, or AI-adoption spend tomorrow. It creates enterprise value because closing the gap converts an unverifiable cost line into a governed one, which is the specific quality a sophisticated buyer prices into, or out of, a deal. A named owner whose own comp depends on an unverified, self-reported result is not a governed line — it is the same gap wearing a different name, and this revision is built to prevent exactly that outcome.

Primary: Operating Partner. Of the four functions this Playbook maps, the Operating Partner is the only one already holding real authority and at least partial incentive, and the only one with standing across the CFO, CHRO, and deal team simultaneously. Secondary: CFO (co-owns the underlying spend data and now holds the independent-verification role — see Section 6, Stage 4), CHRO or portfolio-company President (the most likely candidate to become the named owner for the HR application), employment counsel (a required Stage 2 reviewer whenever the named owner's incentive touches a personnel-related metric), Board and Investment Committee (receive the annual exhibit, hold defined decision rights at escalation, and approve the resourcing commitment before rollout).

Use this Playbook when: a G&A line exceeds roughly 1% of operating expense, or has grown faster than revenue for two consecutive years, and no one in the company can currently state — in a number, not a narrative — what last year's increase in that line produced.

A note on these numbers: the 1% threshold, the two-year growth window, and every other numeric parameter in this document (the six-week diagnostic window, the two-quarter escalation trigger, the thirty-day succession window) are starting defaults, not benchmarked standards. None of them are derived from the underlying research the way the EBITDA and engagement figures are. They exist so a portfolio company has somewhere to start on day one. A sponsor with better information about its own portfolio should adjust them, and should treat that adjustment as a normal part of adoption, not a deviation from the Playbook.

Do not use this Playbook to: redesign the underlying function, benchmark compensation, select an HRIS or other vendor, or build a workforce plan. Those are execution efforts with their own cadence and risk profile; this Playbook governs ownership, measurement, and verification — not delivery.

Required preconditions: an Operating Partner assigned to the company with confirmed bandwidth (Section 9a), a CFO willing to share G&A budget detail by category and serve as independent verifier, employment counsel availability for the Stage 2 gate, and financial or HR reporting that is queryable even if unsophisticated.

Expected outcome: within twelve months, every G&A line above the materiality threshold has a single named owner holding all four conditions, a live and independently-verified outcome hypothesis, and a quarterly track record.

Typical implementation mistakes: treating the Diagnostic as a one-time audit rather than a standing governance motion; naming an owner without formally updating that person's incentive structure; writing an outcome hypothesis too vague to fail, or one with no stated counterfactual; skipping the independent-verification step because the named owner's self-report seems obviously accurate; and mistaking this Playbook for a cost-cutting mandate, which it is not.

Stage 1 — Diagnose (Weeks 1–2). Purpose: Establish, with evidence rather than impression, whether the target line is actually ungoverned. Inputs: Two years of spend by category from the CFO, current org chart, any existing staffing benchmark. Executive decisions: Which G&A lines clear the materiality threshold this cycle. Start with one line — for the pilot, HR — rather than attempting the full portfolio company's G&A stack at once. Actions: Run the Ownership Gap Diagnostic (Section 7) against the target line. For each of the four functions — CFO, CHRO, deal team, Operating Partner — mark Information, Authority, Incentive, and Accountability as Yes, Partial, or No. Outputs: A dated, completed Diagnostic scorecard. Governance checkpoint: None required yet — this stage is diagnostic, not decision-making. Evidence of progress: A completed scorecard exists and has been reviewed by the Operating Partner. Failure indicator: The scorecard is completed but never shared with the functions it maps — it becomes a private observation instead of the basis for Stage 2.

Stage 2 — Assign Ownership (Weeks 3–4). Purpose: Convert the Diagnostic's finding into a single accountable role. Inputs: The completed scorecard from Stage 1. Executive decisions: Who becomes the named owner. In most companies this is whoever already holds the most Information and Authority — typically the CFO or CHRO for the HR application — rather than a newly created role. Whether this line's outcome hypothesis will touch a personnel-related metric (it will, for HR). Actions: The Operating Partner has a direct conversation with the proposed owner and frames it as governance parity with procurement and working capital, not an audit. If the metric involves a personnel-related outcome — engagement, retention, turnover, or anything that could later intersect with a termination, compensation, or benefits decision — the proposed incentive change is routed to employment counsel for review before it is submitted. Counsel is checking one thing specifically: that tying compensation to this metric does not create exposure that a later personnel decision was influenced by the incentive rather than made on its merits. Only after counsel clears the structure does the Operating Partner formally request the sponsor update the owner's incentive or review criteria. Outputs: A named owner, on record; a documented incentive change, cleared by counsel where required, submitted to whoever administers compensation. Governance checkpoint: Operating Partner sign-off that all four conditions are now held by one role, and counsel sign-off where the metric is personnel-related. Neither sign-off is optional; a line is not considered assigned until both exist. Evidence of progress: The incentive change is submitted with counsel's clearance attached, not just discussed. Failure indicator: An owner is named verbally but the incentive change is deferred "until next cycle," or the counsel review is skipped because the metric "seems fine." Both are Stage 2 blockers, not Stage 3 nice-to-haves.

Stage 3 — Establish the Outcome Hypothesis (Weeks 5–6). Purpose: Make the spend trajectory falsifiable — and distinguishable from what would have happened regardless. Inputs: The named owner's knowledge of the function, the current spend trajectory, any existing internal metrics, the trend line for the target metric over the prior two years. Executive decisions: What quantified target defines success or failure over the next twelve months; what the metric would plausibly do with no change in spend (the counterfactual); and what independent data source will be used to check it. Actions: The named owner drafts a one-page Outcome Hypothesis memo with three required elements: a specific, quantified target (for example, "engagement above 22% by Q4"); a stated counterfactual — what the metric would likely read absent this initiative, based on its prior trend; and a named data source the owner does not personally control (the existing employee survey administered by a third party, not a number the owner compiles themselves). A hypothesis that only states a target, with no counterfactual and no independent source, is returned, not accepted. Outputs: A signed, dated Outcome Hypothesis memo carrying all three elements. Governance checkpoint: The Operating Partner rejects any hypothesis missing a quantified target, a stated counterfactual, or an independent data source. Evidence of progress: A hypothesis exists that a skeptical third party could evaluate as met, missed, or merely consistent with the pre-existing trend — without further interpretation from the named owner. Failure indicator: The hypothesis is written broadly enough to be declared "met" regardless of outcome, or its data source is something only the named owner can produce.

Stage 4 — Govern and Verify (Quarterly, ongoing). Purpose: Keep the Diagnostic alive, and keep its results honest. Inputs: The Outcome Hypothesis memo, the named owner's monthly tracking log, the independent data source named in Stage 3. Executive decisions: Whether actual performance is tracking to hypothesis and ahead of the stated counterfactual; whether the miss, if any, has an approved explanation; whether escalation is triggered. Actions: A fixed, brief quarterly review between the Operating Partner and the named owner. Before any quarter is recorded as "met," the CFO — or another party independent of the named owner — confirms the result against the named data source. The named owner's own report is an input to this review, not the verdict. Two consecutive quarters of unexplained miss, or one quarter where the independent verifier cannot confirm the owner's reported result, trigger automatic escalation to the Investment Committee under the defined decision rights in Section 8. Outputs: A quarterly tracking log carrying both the owner's report and the independent verification; an escalation memo if triggered. Governance checkpoint: This review is the checkpoint — add it to the existing portfolio review calendar rather than scheduling it separately. Evidence of progress: The review happens on schedule every quarter, and the independent verification is present every time, not only when a result looks surprising. Failure indicator: The quarterly review happens but the independent-verification step is quietly skipped because "the number looked right" — this defeats the purpose of the step as surely as skipping the review entirely.

Stage 5 — Reconcile, Succeed, and Scale (Month 12). Purpose: Close the loop on the first line, protect it against the named owner's departure, and decide whether to extend the Playbook to a second line. Inputs: A full year of independently-verified quarterly tracking logs. Executive decisions: Whether the hypothesis was met against its counterfactual; what changes for next year's cycle; which G&A line — procurement, working capital, AI-adoption spend — becomes the next application of this Playbook; and confirmation that a succession path exists for the named owner role. Actions: Produce the annual spend-to-outcome reconciliation exhibit, independently verified and staged to be diligence-ready rather than assembled under deadline. Present it to the Board. Confirm the standing succession protocol: if the named owner departs at any point, the four conditions of ownership revert provisionally to the Operating Partner on the owner's exit date, and a successor must be named within thirty days — this protocol should be reconfirmed annually, not assumed to still hold. Outputs: A diligence-ready, independently-verified exhibit; a decision on the next line to govern; a reconfirmed succession protocol. Governance checkpoint: Board review of the exhibit and the succession protocol together. Evidence of progress: The exhibit can answer, cold, "what did this spend produce, and how do we know" — the original test this Playbook exists to pass, now including the verification question an IC will actually ask. Failure indicator: The exhibit has to be reconstructed from scratch because quarterly logs weren't current, or the company discovers mid-year that the named owner left months earlier and no one had reassigned ownership.

The Ownership Gap Diagnostic, operationalized with two bright-line rules, not one.

Rule one (unchanged): any function-condition cell marked "No" in the Incentive or Accountability column, for a line above the materiality threshold, triggers a mandatory reassignment before that line can be considered governed.

Rule two (new): a line is not considered governed — regardless of Rule One — until its outcome hypothesis carries a stated counterfactual, an independent data source, and a verification step performed by someone other than the named owner. A named owner with a self-graded, uncounterfactualized metric has not closed the Ownership Gap; they have simply moved it from "no one is accountable" to "the accountable person grades their own work." Both conditions must hold for a line to pass.

How to use it: Complete the four-by-four scorecard for the target line, then confirm the Stage 3 hypothesis carries all three required elements and the Stage 4 verification step is actually occurring. A line can fail this framework two ways — an empty Incentive/Accountability cell, or a hypothesis nobody but the owner can check — and both are treated as equally disqualifying. When to use it: At Stage 1 for every new line, at every quarterly review to confirm verification is occurring, and again at the Stage 5 annual reconciliation to confirm ownership hasn't quietly drifted back to distributed or unverified. Who owns each decision: The Operating Partner owns the decision to run the Diagnostic and designate the named owner. The sponsor, via the Board or comp committee, owns the incentive-structure change, subject to counsel clearance where required. The CFO owns the independent-verification role by default, unless a conflict of interest makes that inappropriate, in which case the Operating Partner names an alternative verifier at Stage 2. How disagreements resolve: If the CFO and CHRO both believe the other should be named owner, the Operating Partner makes the final call based on which function already holds more Information and Authority per the completed scorecard. If a named owner disputes the independent verifier's finding, the dispute is resolved by the Operating Partner using the named data source as the deciding evidence — not by further discussion between the owner and verifier.

Decision rights: The Operating Partner decides when the Diagnostic runs and who is named owner. The named owner decides the specific content of the outcome hypothesis, subject to the Operating Partner's falsifiability check and counsel's review where required. The CFO (or named alternative) decides, independently, whether a quarter's result is verified. Information flow: The named owner and CFO jointly maintain the underlying spend and outcome data; the Operating Partner receives it quarterly, not continuously — this is a governance cadence, not a live dashboard. Authority: The Operating Partner's authority to require the Diagnostic and designate ownership is presumed under this Playbook for a company already under Operating Partner coverage. Employment counsel holds a defined veto over incentive structures touching personnel metrics, exercised only at Stage 2, not on an ongoing basis. Accountability: The named owner reports quarterly; the CFO verifies quarterly; the Operating Partner presents annually to the Board. Investment Committee decision rights at escalation (new — this closes the gap in the prior version, where escalation had a trigger but no defined outcome). On a two-consecutive-quarter unexplained miss, or a verification failure, the Investment Committee selects from a defined set of responses rather than open-ended discussion: (1) require a remediation plan from the named owner with a new deadline, not to exceed two quarters; (2) reassign the named owner role, invoking the Stage 5 succession protocol immediately rather than waiting for a departure; (3) freeze further budget growth on that specific line pending resolution; or (4) accept the miss with a documented rationale entered into the annual exhibit, reserved for cases where the counterfactual itself has shifted for reasons outside the owner's control. The IC is not required to choose only one — a remediation plan and a budget freeze can run together — but the response must be one or more of these four, on the record, within thirty days of escalation. Board involvement: Annual, via the reconciliation exhibit — unless an escalation occurs, in which case the Board or IC hears it immediately and exercises the decision rights above. Review process: Fixed quarterly cadence between the Operating Partner, the named owner, and the independent verifier; this three-way review is the mechanism that sustains the principle — remove any one of the three roles and the Ownership Gap reopens within a year.

Daily: None. Adding a daily cadence would turn a lightweight governance instrument into an operating burden no one sustains — resist it explicitly. Weekly: None structurally required; the named owner may track leading indicators informally. Monthly: The named owner updates an internal log against the outcome hypothesis — a five-minute entry, not a report. Quarterly: The Operating Partner, named owner, and independent verifier review hypothesis-versus-actual-versus-counterfactual. The assumption re-underwritten at this checkpoint: is this line still governed, still verified, and still ahead of what would have happened anyway. Annually: Full Diagnostic re-run across the portfolio company's top G&A lines; the reconciliation exhibit is finalized, independently verified, and staged for the Board and for future diligence; the succession protocol is reconfirmed.

This Playbook's cost is not zero, and a sponsor should see the real number before approving rollout across a portfolio, not just the per-company estimate. Per governed line, per company, per quarter: roughly 30 minutes for the named owner's monthly log (10 minutes × 3 months), 15 minutes for the CFO's independent verification, and 15 minutes for the Operating Partner's quarterly review — call it one hour of combined time per line per quarter, plus a one-time 4–6 hours across Stages 1 through 3 in the first cycle. For an Operating Partner covering six portfolio companies, each running this Playbook against two governed lines by year two, that is roughly 24 hours of standing quarterly commitment annually across the covered portfolio, plus 48–72 hours of one-time setup as new lines are added — a real but bounded addition to a coverage load this desk's own research already shows is stretched. A sponsor should run this arithmetic against its own portfolio size and Operating Partner coverage ratio before committing to a rollout timeline, rather than accepting the per-company estimate as automatically scalable.

Leading indicators: Percentage of top-five G&A lines with a completed Diagnostic scorecard. Percentage of named owners with a formally updated, counsel-cleared incentive structure. Percentage of quarterly results carrying independent verification, not just an owner's self-report. Time elapsed between Stage 1 and Stage 3 completion (default target: under six weeks, adjustable per Section 5). Lagging indicators: EBITDA realized against the McKinsey-benchmarked composition gap for each governed line, net of what the stated counterfactual would have produced. Number of consecutive quarters a governed line has met its outcome hypothesis under independent verification. Executive KPIs: Percentage of the portfolio company's top five G&A lines carrying a single named owner across all four conditions and a verified, counterfactualized hypothesis — target 100% within twelve months. Board KPIs: The annual reconciliation exhibit — whether it exists, on schedule, independently verified, without a scramble. Whether the succession protocol was reconfirmed. Buyer diligence indicators: Time required to produce a defensible, independently-verified spend-to-outcome answer when asked in a data room — target is the same meeting, not a follow-up a week later.

Incentive not actually updated, or updated without counsel clearance. The most common failure, because it requires follow-through beyond the Operating Partner's direct control. Recovery: both the incentive change and counsel clearance are Stage 2 exit conditions, not parallel tasks that can lag indefinitely. Self-graded results. A named owner reports their own success against their own hypothesis, with no independent check — the gap re-opens under new branding. Recovery: the Stage 4 independent-verification step is mandatory for every quarter, not a spot-check reserved for suspicious results. Hypothesis with no counterfactual. The metric moves for reasons unrelated to the initiative, and the company credits itself anyway. Recovery: the Operating Partner rejects any hypothesis at Stage 3 that doesn't state what the metric would likely do absent the change. Succession vacuum. The named owner leaves — a base-rate event, not an edge case, given how often portfolio-company leadership turns over during a hold — and ownership silently reverts to no one until someone notices at the next annual review. Recovery: the Stage 5 succession protocol reverts ownership to the Operating Partner automatically on the owner's exit date, with a thirty-day clock to name a successor. Legal exposure from an unreviewed incentive structure. A personnel-related metric gets tied to compensation without counsel input, and later complicates the defensibility of an unrelated HR decision. Recovery: the Stage 2 counsel gate is non-negotiable for any personnel-related metric. Diagnostic becomes a checkbox exercise. Run once at rollout, never revisited. Recovery: hard-wire the quarterly review into the existing portfolio review calendar. Leadership behavior that quietly undermines implementation: an Operating Partner who accepts a self-reported result without asking the verifier to confirm it teaches the organization that verification is theater. The single highest-leverage leadership behavior in this Playbook is the Operating Partner's willingness, in the first quarterly review, to ask the independent verifier directly — every time, not only when something looks off. Early warning signs: A quarterly review happens but the verifier's sign-off is missing from the log. The named owner's update references activity rather than the hypothesis's metric. The annual exhibit takes more than a week to assemble because logs weren't current. No one can say, on request, who the named owner's successor would be if that person left tomorrow.

A buyer evaluating a portfolio company that has run this Playbook for even two or three quarters finds a data room that answers "what did this spend produce, and how was that verified" with a document, not a conversation. Diligence questions about G&A composition and management-team quality — the two categories most PE professionals already credit with determining deal outcomes — become answerable on the spot, with an independent verification trail rather than a self-report a buyer's own diligence team would otherwise have to reconstruct. Because the governance and the succession protocol both live in the role rather than in a particular person, the capability transfers across a management change — itself a confidence signal given how often portfolio-company leadership turns over mid-hold. The net effect is the direct removal of what buyers actually discount for — unverifiability — with the independent-verification step removing the second-order version of the same risk: a verification-in-name-only process a sharp buyer's team would see through immediately.

Standardize across every company, without exception: the four-condition Diagnostic, the Stage 2 counsel gate for personnel-related metrics, the Stage 3 counterfactual-and-independent-source requirement, the Stage 4 independent-verification step, the succession protocol, and the Investment Committee's defined decision rights at escalation. These are the mechanisms that separate a governed line from a documented intention, and they are the first things a sponsor under time pressure will be tempted to soften — resist that at the portfolio level even where an individual company pushes back. Customize per company: who is named owner, the specific content of each outcome hypothesis, and the numeric defaults in Section 5, which should be recalibrated to each portfolio company's actual scale and data maturity. Smaller portfolio companies: where a dedicated CHRO or full four-function org chart doesn't exist, the named owner defaults to the CEO or CFO directly, and the independent verifier defaults to the Operating Partner rather than the CFO — the Diagnostic and both bright-line rules still apply in full; only the specific people change. Resourcing at scale: use the model in Section 9a before committing a rollout timeline across more than two or three portfolio companies at once — the standing quarterly commitment compounds faster than the per-company estimate suggests.

This Playbook establishes the permanent operating capability of converting an Ownership Gap finding into an executable, independently-verified governance motion — Diagnose, Assign, Hypothesize, Govern and Verify, Reconcile and Succeed — that any future Playbook in this franchise can reuse without modification. The addition of the counterfactual requirement, the independent-verification step, the succession protocol, and the defined IC decision rights at escalation are now part of that reusable core, not one-off fixes specific to HR — every future application (procurement, working capital, AI-adoption spend) inherits all of it by default. This is the founding volume of the "Who Owns Operating Value Creation" chapter of the Operating System, and this revision is what makes it durable enough to survive contact with a real Investment Committee.